Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27182005)

Published in J Diabetes Investig on July 08, 2016

Authors

Saori Tsuchiya1, Evan Friedman2, Carol Addy2, Akira Wakana1, Daniel Tatosian2, Yuki Matsumoto1, Hideyo Suzuki1, Eunkyung Kauh2

Author Affiliations

1: MSD K.K., Tokyo, Japan.
2: Merck & Co. Inc, Kenilworth, New Jersey, USA.

Articles cited by this

Prediction of creatinine clearance from serum creatinine. Nephron (1976) 64.02

A systematic review of adherence with medications for diabetes. Diabetes Care (2004) 7.67

Impact of dosage frequency on patient compliance. Diabetes Care (1997) 2.43

The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol (2008) 2.13

Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther (2008) 1.45

Minireview: update on incretin biology: focus on glucagon-like peptide-1. Endocrinology (2010) 1.29

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab (2008) 1.24

Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem (2014) 1.22

Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther (2014) 1.22

Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes. Diabetes Care (2015) 0.94

Incretin physiology and pathophysiology from an Asian perspective. J Diabetes Investig (2014) 0.91

Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy Subjects. J Clin Pharmacol (2016) 0.83